CVS Health schedules November 4 results. CVS Health stock trades 1.13 percent above its prior close

Published on 10/07/2026 at 14:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit USD 106.10 billion in the second quarter, up 7.30 percent year over year. CVS Health stock costs EUR 77.58 on October 7, 2026 after EUR 76.71.

Fotorealistisches CGI-Rendering eines modernen Glas-Stahl-Bürogebäudes mit Grünanlage — CVS Health Corp. modernes Unternehmensgebäude als Architektur-Render mit moderner Glas-Stahl-Fassade, ISIN US1266501006, Illustration mit AI erstellt.

CVS Health Corp. (ISIN US1266501006) was trading at EUR 77.58 at Lang & Schwarz on October 7, 2026 at 2:33 p.m. CEST, plus 1.13 percent versus the prior close of EUR 76.71. According to MarketWatch, CVS Health will report third-quarter 2026 results on November 4, 2026.

November 4 results date

The scheduled report gives the next clear test of CVS Health's insurance, pharmacy and health-services businesses. The company describes these operations as connected services spanning health insurance, pharmacy, prescription drug coverage and care delivery, according to CVS Health.

MarketWatch lists a current-quarter earnings-per-share estimate of USD 1.63 and a full-year 2026 estimate of USD 8.00. The November report therefore matters for whether the second-half outlook remains aligned with those estimates.

Second-quarter revenue reached USD 106.10 billion

In the second quarter of 2026, CVS Health reported revenue of USD 106.10 billion, up 7.30 percent from the same period a year earlier, according to MarketBeat. The same report said quarterly earnings per share reached USD 2.58 versus a USD 1.87 consensus estimate, a USD 0.71 beat.

MarketBeat also reported full-year 2026 adjusted earnings-per-share guidance of USD 7.90-8.10. That range gives the November results a direct benchmark: the reported quarter must support the company's earnings path rather than only revenue growth.

Target remains above the current quote

MarketBeat said 22 of 23 analysts rated CVS Health a Buy and placed the average 12-month target at USD 107.24. The source also cited a quarterly dividend of USD 0.665, with an ex-dividend date of October 22, 2026.

CVS Health's primary-market context remains the NYSE in USD. The stock's market capitalization was USD 110.3 billion on October 6, 2026, while its 52-week range was USD 69.51 to USD 110.68. The euro quote is a separate German-market reference for investors tracking the shares from Europe.

CVS Health stock rises in trading

At Lang & Schwarz, CVS Health was trading at EUR 77.58 on October 7, 2026 at 2:33 p.m. CEST, plus 1.13 percent versus the prior close of EUR 76.71. The further course of trading is shown by the continuously updated real-time quote of CVS Health stock.